Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

INMB

INmune Bio Inc

May 10 • 04:00PM ET

10.02

Dollar change -0.75
Percentage change -6.96	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF ONEQ IWC AVSC DFSU DCOR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.92	Insider Own	35.35%	Shs Outstand	17.95M	Perf Week	-13.40%
Market Cap	198.00M	Forward P/E	-	EPS next Y	-2.56	Insider Trans	0.10%	Shs Float	12.78M	Perf Month	-8.41%
Income	-34.50M	PEG	-	EPS next Q	-0.63	Inst Own	12.47%	Short Float	13.56%	Perf Quarter	-16.98%
Sales	0.13M	P/S	1523.04	EPS this Y	-61.08%	Inst Trans	-4.42%	Short Ratio	15.00	Perf Half Y	37.64%
Book/sh	1.62	P/B	6.20	EPS next Y	5.02%	ROA	-57.11%	Short Interest	1.73M	Perf Year	14.91%
Cash/sh	1.32	P/C	7.62	EPS next 5Y	-	ROE	-81.82%	52W Range	6.50 - 14.74	Perf YTD	-11.01%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-5.50%	ROI	-117.40%	52W High	-32.02%	Beta	1.94
Dividend TTM	-	Quick Ratio	1.71	Sales past 5Y	321.24%	Gross Margin	-	52W Low	54.15%	ATR (14)	0.87
Dividend Ex-Date	-	Current Ratio	1.71	EPS Y/Y TTM	-27.74%	Oper. Margin	-26209.92%	RSI (14)	43.13	Volatility	6.72% 9.27%
Employees	17	Debt/Eq	0.27	Sales Y/Y TTM	-47.39%	Profit Margin	-26333.59%	Recom	1.33	Target Price	19.67
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-67.93%	Payout	-	Rel Volume	1.29	Prev Close	10.77
Sales Surprise	-50.00%	EPS Surprise	-14.02%	Sales Q/Q	-63.16%	Earnings	May 09 AMC	Avg Volume	115.52K	Price	10.02
SMA20	-4.47%	SMA50	-9.64%	SMA200	3.17%	Trades		Volume	148,564	Change	-6.96%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-01-23	Initiated	Robert W. Baird	Outperform	$16
May-24-22	Downgrade	B. Riley Securities	Buy → Neutral	$14 → $7
Jul-07-21	Reiterated	Maxim Group	Buy	$32 → $42
Apr-21-21	Initiated	B. Riley Securities	Buy	$29
Jan-22-21	Reiterated	Maxim Group	Buy	$16 → $32
Sep-01-20	Initiated	BTIG Research	Buy	$23
Jul-15-20	Reiterated	H.C. Wainwright	Buy	$7 → $20

May-09-24 04:05PM	INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update (GlobeNewswire)
May-07-24 08:00AM	INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9 (GlobeNewswire)
Apr-30-24 08:00AM	INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro Under Compassionate Use for Over Three Years (GlobeNewswire)
Apr-29-24 08:00AM	INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
Apr-25-24 09:00AM	INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
08:00AM	Loading…
Apr-23-24 08:00AM	INmune Bio Inc. Announces 24-Month Stability Validation of XPro for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay (GlobeNewswire)
Apr-22-24 08:00AM	INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering (GlobeNewswire) +26.94%
Apr-08-24 08:00AM	INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024 (GlobeNewswire)
Apr-01-24 10:20AM	INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 05:31PM	INmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancements (GuruFocus.com)
Mar-28-24 08:53PM	INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:01PM	INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update (GlobeNewswire)
Mar-26-24 04:01PM	INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28 (GlobeNewswire)
Mar-13-24 08:00AM	INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy (GlobeNewswire)
Mar-05-24 08:00AM	INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro (GlobeNewswire) -5.37%
09:00AM	Loading…
Feb-12-24 09:00AM	INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-06-24 09:00AM	INmune Bio to Participate in Baird's Biotech Discovery Series Webcast on February 13, 2024 (GlobeNewswire)
Jan-30-24 08:00AM	INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease Program (GlobeNewswire) -7.52%
Jan-16-24 08:30AM	ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology (GlobeNewswire) -6.72%
Jan-02-24 08:00AM	INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune in Patients with Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
Dec-18-23 04:01PM	INmune Bio Provides Update Regarding Global Alzheimer's Phase II Clinical Trial and Clinical Hold Issued by the United States FDA (GlobeNewswire) +7.97%
Nov-29-23 08:35AM	Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks (Investor's Business Daily)
08:00AM	INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-27-23 08:00AM	INmune Bio Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease (GlobeNewswire)
Nov-17-23 08:15AM	Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning (Investor's Business Daily)
Nov-15-23 09:00AM	INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer's Disease in Europe (GlobeNewswire)
Nov-02-23 10:11AM	INmune Bio, Inc. (NASDAQ:INMB) Q3 2023 Earnings Call Transcript (Insider Monkey)
09:54AM	Q3 2023 INmune Bio Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-01-23 06:44PM	INmune Bio Inc (INMB) Reports Q3 2023 Financial Results (GuruFocus.com)
04:10PM	INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update (GlobeNewswire)
08:00AM	Loading…
Oct-31-23 08:00AM	INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune Therapeutic Composition given Favorable Patentability Opinion by International Search Authority (GlobeNewswire) +7.84%
Oct-30-23 09:07AM	INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRP (GlobeNewswire)
Oct-25-23 09:00AM	Cumulus Neuroscience Presents Data at CTAD 2023 Annual Meeting (PR Newswire)
Oct-17-23 08:00AM	INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro to Treat Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire) +10.32%
Oct-16-23 09:00AM	INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1 (GlobeNewswire)
Sep-07-23 09:00AM	INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Sep-05-23 08:00AM	INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimers Disease (GlobeNewswire)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey) -5.82%
Aug-08-23 09:07AM	INmune Bio, Inc. (NASDAQ:INMB) Q2 2023 Earnings Call Transcript (Insider Monkey) -10.39%
06:33AM	Q2 2023 INmune Bio Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 04:00PM	INmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business Update (GlobeNewswire)
Aug-01-23 08:00AM	INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-31-23 08:00AM	INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7 (GlobeNewswire)
Jul-12-23 08:00AM	INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference. (GlobeNewswire) -6.94%
Jul-11-23 08:00AM	INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimers Disease (GlobeNewswire) +14.16%
Jul-10-23 04:00PM	INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro Promotes Remyelination by Affecting Astroglial and Microglial Biology (GlobeNewswire)
May-24-23 09:00AM	INmune Bio Inc.s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy (GlobeNewswire)
May-08-23 08:00AM	INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
May-05-23 06:15AM	INmune Bio First Quarter 2023 Earnings: US$0.36 loss per share (vs US$0.39 loss in 1Q 2022) (Simply Wall St.) +6.61%
May-04-23 08:13AM	Q1 2023 INmune Bio Inc Earnings Call (Thomson Reuters StreetEvents)
May-03-23 04:10PM	INmune Bio Inc. Announces First Quarter 2023 Results and Provides Business Update (GlobeNewswire) -5.60%
Apr-30-23 08:34AM	A number of insiders bought INmune Bio, Inc. (NASDAQ:INMB) stock last year, which is great news for shareholders (Simply Wall St.)
Apr-24-23 09:00AM	INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3 (GlobeNewswire)
Apr-19-23 08:30AM	XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimers Disease (GlobeNewswire)
Apr-11-23 08:00AM	INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03 (GlobeNewswire) +6.67%
Apr-03-23 09:00AM	INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire) +6.97%
Mar-20-23 06:46AM	INmune Bio, Inc.'s (NASDAQ:INMB) top owners are retail investors with 55% stake, while 25% is held by insiders (Simply Wall St.) -5.78%
Mar-06-23 09:48AM	INmune Bio, Inc. (NASDAQ:INMB) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-03-23 09:53AM	Q4 2022 INmune Bio Inc Earnings Call (Thomson Reuters StreetEvents) -7.31%
Mar-02-23 04:05PM	INmune Bio, Inc. Announces 2022 Results and Provides Business Update (GlobeNewswire)
Feb-21-23 09:00AM	INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2 (GlobeNewswire)
Feb-08-23 08:45AM	INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom (GlobeNewswire) +10.05%
Jan-25-23 07:45AM	INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy (GlobeNewswire) +9.33%
Dec-22-22 08:00AM	INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimers Disease (GlobeNewswire)
Dec-21-22 09:55AM	Wall Street Analysts Predict a 99% Upside in INmune Bio, Inc. (INMB): Here's What You Should Know (Zacks)
Dec-08-22 08:00AM	INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune (GlobeNewswire) +6.56%
Dec-06-22 04:00PM	INmune Bio, Inc. Reports Combination Therapy with INB03 Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer (GlobeNewswire)
Nov-29-22 08:00AM	INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimers Disease Treatments (GlobeNewswire)
Nov-20-22 07:34AM	Quite a few insiders invested in INmune Bio, Inc. (NASDAQ:INMB) last year which is positive news for shareholders (Simply Wall St.)
Nov-14-22 09:00AM	INmune Bio, Inc. Receives Health Canada No Objection Letter to Commence Clinical Trial of XPro1595 in Mild Alzheimers Disease (GlobeNewswire)
Nov-02-22 04:00PM	INmune Bio, Inc. Announces Third Quarter 2022 Results and Provides Business Update (GlobeNewswire) -6.96%
Oct-26-22 08:10AM	INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2 (GlobeNewswire)
Oct-19-22 11:48AM	INmune Bio's INKmune Shows Positive Efficacy In Multiple Cancer Cell Lines (Benzinga)
08:00AM	INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune (GlobeNewswire)
Oct-10-22 11:46AM	While insiders own 25% of INmune Bio, Inc. (NASDAQ:INMB), individual investors are its largest shareholders with 54% ownership (Simply Wall St.)
Sep-07-22 09:00AM	INmune Bio, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference and the Baird Global Healthcare Conference (GlobeNewswire) +6.33%
Aug-04-22 05:00AM	INmune Bio, Inc. (INMB) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-03-22 04:10PM	INmune Bio, Inc. Announces Second Quarter 2022 Results and Provides Business Update (GlobeNewswire)
Jul-27-22 08:00AM	INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, August 3 (GlobeNewswire)
Jul-25-22 08:00AM	INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in Two Upcoming Panels on Alzheimer's Disease (GlobeNewswire)
Jul-17-22 08:19AM	INmune Bio (NASDAQ:INMB) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway (Simply Wall St.)
Jun-22-22 08:00AM	USPTO Issues Patent Covering Use of XPro for Treatment of CNS Diseases (GlobeNewswire)
Jun-16-22 08:00AM	INmune Bio, Inc. Presents Data on Combination Therapy with INB03 on Overcoming Resistance to HER2 Targeted Therapies in Breast Cancer (GlobeNewswire)
Jun-09-22 07:35AM	Mizner Park office space fills up (American City Business Journals) +7.61%
Jun-07-22 09:55AM	Can INmune Bio, Inc. (INMB) Climb 105% to Reach the Level Wall Street Analysts Expect? (Zacks)
08:36AM	New Analysts Initiate Coverage: 5 Stocks for Higher Returns (Zacks)
Jun-02-22 06:22AM	CFO, Treasurer & Secretary David Moss Just Bought A Handful Of Shares In INmune Bio, Inc. (NASDAQ:INMB) (Simply Wall St.)
May-25-22 12:07PM	INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study (Zacks) +12.59%
10:06AM	Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates (Zacks)
May-24-22 08:59AM	INmune Bio stock plunges after clinical hold of IND of Alzheimer's treatment prompts analyst downgrade (MarketWatch) -24.62%
May-23-22 04:00PM	INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as Part of IND Application for XPro1595 in Alzheimers Disease (GlobeNewswire)
May-18-22 09:00AM	INmune Bio, Inc. to Present at the H.C. Wainwright Global Hybrid Investment Conference on May 24th (GlobeNewswire)
May-10-22 08:00AM	INmune Bio, Inc. Presents Data Demonstrating XPro Promotes Remyelination in Gray Matter at 3rd European Conference on Neuroinflammation (GlobeNewswire)
May-06-22 01:30PM	INmune Bio, Inc. (INMB) Q1 2022 Earnings Call Transcript (Motley Fool)
May-05-22 04:00PM	INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business Update (GlobeNewswire) -8.48%
May-03-22 11:44AM	What Type Of Shareholders Make Up INmune Bio, Inc.'s (NASDAQ:INMB) Share Registry? (Simply Wall St.)
Apr-28-22 07:00AM	INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5 (GlobeNewswire) +6.84%
Apr-25-22 04:00PM	INmune Bio, Inc. to Participate at the B. Riley Neuro & Ophthalmology Conference (GlobeNewswire) +16.20%
Apr-14-22 03:38PM	INmune (INMB) Begins Dosing in Mid-Stage Study With AD Candidate (Zacks)
Apr-13-22 04:00PM	INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimers disease (GlobeNewswire) +12.12%

INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer's disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Juda Scott	Director	Nov 10 '23	Buy	6.95	7,000	48,650	37,000	Nov 13 11:31 AM
Schroeder Timothy j	Director	Jul 12 '23	Sale	11.01	10,000	110,085	82,187	Jul 14 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INMB

INmune Bio Inc

Upgrade your FINVIZ experience